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We describe a case of human ehrlichiosis in a lung transplant
recipient and review published reports on ehrlichiosis in immu-
nocompromised patients. Despite early therapy with doxycy-
cline, our patient had unusually severe illness with features of
thrombotic thrombocytopenic purpura. Of 23 reported cases of
ehrlichiosis in immunocompromised patients, organ failure
occurred in all patients and 6 (25%) died.
ince the discovery in 1987 of Ehrlichia as a cause of tick-
borne disease in humans (1), ehrlichiosis has been recog-
nized as an increasingly important cause of acute febrile ill-
ness (2,3). The two main pathogenic species are Ehrlichia
chaffeensis, which causes human monocytic ehrlichiosis
(HME), and the as-yet-unnamed agent of human granulocytic
ehrlichiosis (HGE) (4). A third species, E. ewingii, which has
been recently described, causes clinical disease indistinguish-
able from infection caused by E. chaffeensis or the agent of
human granulocytic ehrlichiosis (5).
Delineation of the epidemiology of human ehrlichiosis has
greatly enhanced our understanding of this emerging infection.
However, information on the manifestations of ehrlichiosis in
immunocompromised patients is limited. We report a case of
severe monocytic ehrlichiosis in a lung transplant recipient
who had pancytopenia, acute renal failure, and encephalopa-
thy. Despite early diagnosis and treatment with doxycycline,
his illness progressed and took on features of thrombotic
thrombocytopenic purpura (TTP). A review of reported cases
of Ehrlichia infection in immunocompromised patients shows
that the infection is far more severe in this population and is
often fatal.
Case Report
A 38-year-old man with cystic fibrosis had undergone
bilateral lung transplantation in 1998 and had been well. In
September 2000, he visited a physician with a 3-day history of
fever as high as 38.3°C, myalgias, and headache. A resident of
Columbia, Missouri, the patient had spent much time outdoors
but did not recall tick infestation or recent tick bite. His medi-
cations included cyclosporine, mycophenolate, prednisone,
diltiazem, trimethoprim-sulfamethoxazole, and valacyclovir.
On physical examination, the patient appeared acutely ill
with temperature 38.3° C, blood pressure 140/64, heart rate
110 per minute, and respiratory rate 20 per minute. He was
lethargic but could follow commands, and his neurologic exam
was unremarkable. Fine bibasilar crackles were present bilat-
erally, but heart sounds were normal. Examination of the abdo-
men was negative. Synovitis was not evident, and no
cutaneous lesions were found.
The leukoctye count was 3.7x109 per L with 68% neutro-
phils, hemoglobin was 64 g/L, and platelet count was 23,000/
L. Serum creatinine was 4.6 mg/dL, aspartate aminotrans-
ferase 420 U/L, alanine aminotransferase 96 U/L, and bilirubin
3.2 mg/dL. International normalized prothrombin time ratio
(INR) was 1.4. Examination of a peripheral blood smear
showed schistocytes and other microangiopathic changes.
Multiple blood cultures were negative. Cytomegalovirus
DNA was not detected in peripheral blood. Noncontrast com-
puted tomography of the brain was normal. Chest radiograph
showed bilateral infiltrates.
The patient was treated initially with intravenous piperacil-
lin-tazobactam and vancomycin. Cyclosporine and trimethop-
rim-sulfamethoxazole were discontinued. The next day, his
mental status continued to deteriorate. Lumbar puncture was
deferred because of thrombocytopenia. Antibiotic therapy was
changed to intravenous meropenem. Four days after admis-
sion, the bone marrow was examined because of worsening
pancytopenia; intracytoplasmic morulae were seen in monocy-
toid cells, characteristic of monocytic ehrlichiosis (Figure).
Leukocytes in a peripheral blood smear also contained moru-
lae. Intravenous doxycycline was begun for treatment of pre-
sumed  Ehrlichia infection. Whole-blood polymerase chain
reaction (PCR) (Viromed, Minneapolis, MN) in the first week
of illness was subsequently reported positive for E. chaffeensis
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Figure. Bone marrow examination (Wright's stain x1000). Intraleuko-
cytic morulae of Ehrlichia can be seen (arrow) within monocytoid cells.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 321
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DNA. Serology by immunofluorescence antibody testing for
both E. equi and E. chaffeensis performed 2 weeks after onset
of illness was negative, with titers <1:40.
Despite treatment with doxycycline, the patient’s confu-
sion, thrombocytopenia, and microangiopathic anemia did not
improve, and on the fifth hospital day he was transferred to the
University of Wisconsin Hospital and Clinics. Physical exami-
nation showed blood pressure 144/94 mmHg, heart rate 77/
minute, temperature 36.5°C, and respiratory rate 24/minute.
Multiple ecchymoses were present on the torso and extremi-
ties. Neurologic examination was nonfocal. There were coarse
bibasilar crackles in the lungs bilaterally. Examination of the
heart and abdomen was unremarkable.
Leukocytes were 2.9 x 109/L, hemoglobin 86 g/L, and
platelets 30,000/L. Serum creatinine was 6.2 mg/dL (548 mol/
L), total bilirubin 2.0 mg/dL, aspartate aminotransferase 105
U/L, and alanine aminotransferase 55 U/L. INR was 1.1, and
the activated partial thromboplastin time was 26 seconds. A
peripheral blood smear showed numerous fragmented red
blood cells. Chest radiograph showed persistence of bilateral
infiltrates.
The patient’s fever resolved 2 days after doxcycline was
started; however, oliguric renal failure necessitated hemodial-
ysis. Hematologic studies showed progressive microangio-
pathic anemia and thrombocytopenia with a normal INR,
suggestive of TTP, presumably secondary to Ehrlichia infec-
tion. Daily plasmaphereses were begun and continued for 8
weeks. Gradually the hematologic abnormalities and renal
function improved, and the patient’s mental status returned to
normal. Doxycycline was given for 2 weeks.
The patient ultimately made a full recovery with no appar-
ent sequelae. Cyclosporine was not resumed, and he was main-
tained on sirolimus and prednisone to prevent transplant
rejection. No rejection occurred, despite a reduction in immun-
osuppressive therapy during the treatment of Ehrlichia infec-
tion.
Table. Reports of immunocompromised patients with Ehrlichia infection
Immunocompromised state Age Form of ehrlichiosis Clinical features Outcome Reference
Rheumatoid arthritis, on methotrexate 49 Ehrlichia ewingii Fever, headache Survived 5
Emphysema, on prednisone 65 E. ewingii Fever, headache Survived 5
Renal transplant 11 E. ewingii Lyphadenopathy, fever Survived 5
Liver transplant 47 HMEa Multiorgan failure Survived 9
Leukemia 6 HME Hepatitis, pancytopenia, rash, 
renal failure
Survived 10
Asplenia 71 HGE Fever, neurologic dysfunction Survived 11
Asplenia 30 HGE Rash, fever Survived 11
HIV infection (CD4 45/mm3) 33 HME Cardiomyopathy, heart failure Survived 12
Renal transplant 35 HME Rash, pancytopenia, renal failure Survived 13
HIV infection (CD4 NS) 38 HME Multiorgan failure Died 14
Sickle beta-thalassemia NS HME Respiratory failure Survived 15
Renal transplant NS HME NS Survived 15
HIV infection (CD4 164/mm3) 52 HME Hepatitis, thrombocytopenia Died 16
Renal transplant 67 HGE Pancytopenia, renal failure, hepatitis Survived 17
HIV infection CD4 (18/mm3) 36 HME Hepatitis, renal failure Died 18
Liver transplant 51 HME Pancytopenia, shock Survived 19
Asplenia, chronic lymphocytic 
leukemia, on steroids
80 HGE Multiorgan failure Died 7
HIV infection (CD4 199/mm3) 37 HME Fever, pancytopenia, toxic-shock-like 
illness
Survived 20
Splenectomy 46 HME Pancreatitis, shock, encephalitis Survived 20
HIV infection (CD4 64/mm3) 41 HME Pancytopenia, pulmonary hemorrhage Died 21
Asplenia 67 E. canis Renal failur,e respiratory 
failure, encephalitis
Died 8
Crohn disease requiring prednisone 57 E. canis Pancytopenia, hepatitis Survived 22
Bilateral lung transplant 38 HME Pancytopenia, renal failure, 
TTP-like illness
Survived Current case
aHME = human monocytic ehrlichiosis; HGE = human granulocytic ehrlichiosis; NS = not specifiedDISPATCHES
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Ehrlichiosis is a zoonotic illness caused by Ehrlichia spe-
cies, which are pleomorphic, intracellular, rickettsia-like
organisms (2-4). The clinical spectrum of ehrlichisis varies
from a mild, influenzalike illness to a fulminant sepsis syn-
drome, but in most patients is self-limiting and not fatal. Death
rates of documented ehrlichial infection in large, unselected
series have been 1% to 8% (3,6-8). This low rate contrasts
sharply with the high death rate of ehrliochiosis in immuno-
compromised patients (Table). 
Cellular immunity represents the most important host
defense against rickettsial infection (23). Acute-phase sera of
patients with HGE contain elevated levels of interferon
gamma, which is associated with the clearance of Ehrlichia
from peripheral blood (24). In a mouse model of ehrlichiosis,
immunocompromised mice have persistent infection, and most
eventually die (25). Impairment of cellular immunity, whether
from immunosuppresssive therapies or underlying disease,
retards recovery, leading to more severe disease and higher
death rates.
The population of immunocompromised patients is large
and growing; many have asplenia or solid organ or bone mar-
row transplants (26). An analysis of the published reports of
ehrlichial infection shows that the disease in immunocompro-
mised patients is far more severe and prolonged and more
likely to be fatal (Table) (5,7-22). Virtually all these patients
had signs of organ dysfunction, including pancytopenia (40%),
renal failure (24%), respiratory distress (14%), shock (28%),
and neurologic dysfunction (18%). Six (25%) of 23 patients
died; 4 of the 6 deaths were in HIV-infected patients. Two
patients died within 24 hours after coming to medical atten-
tion, despite initiation of appropriate antimicrobial therapy; in
the third, the diagnosis was not considered until late in the hos-
pital course; and in the fourth, the diagnosis was made post-
mortem. Two deaths occurred in asplenic patients; in both,
Ehrlichia infection was not suspected until 1 week after onset
of illness. 
In a recent series of ehrlichial infection in 21 HIV-infected
patients, 6 of which are included in our review, Paddock et al.
reported a high frequency (71%) of moderate to severe disease
in HIV-infected patients, particularly with E. chaffeensis (27).
Low CD4 counts were associated with a poor outcome. 
Discussion
To our knowledge, this is the first reported case of acute
ehrlichiosis in a lung transplant recipient. Our patient had lab-
oratory features typical of Ehrlichia infection (thrombocytope-
nia, leukopenia, and transaminase elevation). However, he also
had microangiopathic anemia, renal failure, and neurologic
dysfunction characteristic of TTP. Ehrlichiosis with features of
TTP has been described in two reports (28,29), one case each
of HME and HGE. Both cases were in immunocompetent per-
sons: one was treated with doxycycline and plasmapheresis; in
the other, the diagnosis was made postmortem.
Our patient’s multiorgan failure and hematologic aberra-
tions persisted, despite doxycycline therapy, until he under-
went plasmapheresis. He was receiving cyclosporine, which is
a well-known cause of a rare hemolytic uremic syndrome-
TTP-like condition that does not respond to plasmapheresis
and nearly always proves fatal (30). That our patient’s TTP-
like illness coincided with Ehrlichia infection and responded
to doxycycline and plasmapheresis makes it most likely that it
was a consequence of acute ehrlichiosis, not cyclosporine.
Neurologic manifestations, ranging from confusion to
frank meningitis, have been reported in up to 20% of patients
with erhlichiosis (31). Our patient had obtundation and delir-
ium that persisted after doxycycline therapy was initiated and
his fever had resolved. The presence of headache and confu-
sion in conjunction with pancytopenia and transaminase eleva-
tion should raise suspicion of Ehrlichia infection, especially if
the patient has had potential tick exposures.
The diagnosis of ehrlichiosis is often delayed because of
its nonspecific clinical and laboratory manifestations. In the
immunocompromised person, the search for opportunistic
infections may further preclude consideration of Ehrlichia
infection. The empiric antimicrobial regimens used in immu-
nocompromised patients for suspected cryptogenic bacterial
and fungal sepsis rarely include a drug or drugs effective
against Ehrlichia. PCR to detect Ehrlichia DNA is invaluable
for the diagnosis and has >90% sensitivity and even better
specificity (32). This technique is particularly useful in the
immunocompromised host in whom rapid diagnosis is of
utmost importance. Peripheral blood and bone marrow exami-
nations show intracellular morulae in HME in only 1% to 5%
of cases and cannot be relied on diagnostically, unless positive.
Serologic testing does not allow rapid diagnosis and may be
negative in the immunocompromised patient (21), as was the
case with our patient. 
The diagnosis of ehrlichiosis should be considered in any
patient with fever, transaminase elevations, and new-onset
thrombocytopenia or leukopenia who has had potential tick
exposures in an endemic area. In the immunocompromised
host, clinical manifestations are more severe and can include
neurologic deterioration, multiorgan failure, and even a TTP-
like illness. Response to appropriate therapy with doxycycline
may be delayed. A high index of suspicion, the use of PCR for
confirmatory diagnosis and early empiric therapy can be life-
saving.
Dr. Safdar is a clinical and research fellow at the University of
Wisconsin, Madison.
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